Infection Congress Market Analysis and Reports | Germany Conference Series

Market Analysis - Infection Congress 2020

Infection Congress 2020 is nonpareil and open platform to explore and gain the knowledge in the field of Life science. This conference brings together professors, researchers, scientists, students in all the areas of medical sciences, pharmaceutical, Life sciences, Medical associations and societies, enables an international forum to explore the approved research. Conference Series is delighted to invite you all to attend and register for the “7th International Congress on Infectious Diseases” scheduled for February 24-25, 2020 at Berlin, Germany.

The organizing committee is gearing up for an exciting and informative conference program this year also which includes plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Infection Congress 2020, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Infection Congress 2020 organizing committee look forward to meeting you in Berlin, Germany.

Infectious Diseases:

Infections are caused by microorganisms resides inside the host body.  The colonization of microbes is beneficial and sometimes fatal, vary according to the host immune resistance and drug susceptibility. In general biologist classified living organisms which are called as bacteria, virus, protozoa, fungi, Parasites, Prions, Viroid’s (plant pathogens, they affect the health of plants). The overlap of the kingdoms in this figure is intentional, because, given the evolution of increasingly complex and diverse species.

Human with infection causing agent inside the body called host and organisms as parasite. These tiny microbes colonize inside the body and reproduce. The organism that causes infection is also called as infectious agent. The resided organism that harms a host's health is often called a pathogen. The infection can be varied to different stages in accordance to various types of infectious agents that establishes successful site of infection in the host cause disease. Infectious agents come in many shapes and sizes. The single celled microscopic organisms are called Bacteria and protozoa, while viruses are even smaller. Fungi grow like plants and helminths that resemble worms.

The death rate of people is more due to infectious diseases than any other single cause. Infectious diseases are caused by microbes. Microbes are tiny living organisms which are ubiquitous and are omnipresent- in air, soil and water. The mode of transmission of infection varies different ways by touching, eating, drinking or breathing something that contains a germ, spread through animal, insect bites, and sexual contact.

The global market for infectious disease treatments totaled $64.8 billion in 2017. The market should total $99 billion by 2022, growing at a compound annual growth rate (CAGR) of 8.9% from 2017 to 2022.

The global infectious disease diagnostics market is expected to reach USD 25.43 billion by 2027 from USD 15.57 billion in 2018, at a CAGR of 5.6%. The increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics are some the factors driving the growth of this market.

The global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis are considerably high in spite of significant improvements in sanitation practices and medicine. Many of the currently available diagnostic techniques are slow, involve complex procedures, and lack specific identification of causative agents. Owing to this, patients receive empiric, broad-spectrum antimicrobial therapy rather than appropriate therapies. This has resulted in the emergence of super-resistant microbes

On the basis of technology, the market is broadly segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and others. The immunodiagnostics segment accounted for the largest share of the global infectious disease diagnostics market in 2018. This dominant share is attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness. On the basis disease type, the market is broadly segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza and others. The hepatitis diagnostics segment accounted for the largest share of the global infectious disease diagnostics market in 2018 and HAIs diagnostics segment is expected to witness the highest CAGR during the forecast period. The growth of HAIs diagnostics is attributed to factors such as the rising burden of MRSA infections; increasing number of new products launched in the market; and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assays, Xpert MRSA NxG, and ARIES C. difficile assays that are based on the PCR technology.

In 2018, North America accounted for the largest share of the global infectious disease diagnostics market. This largest share is attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMérieux (France), Bio-Rad (US), and Roche (Switzerland).

In accordance to IDSA Infectious Diseases Society of America (National Medical Society) & Global Infectious Diseases Association there is an urgent, immediate need for new therapeutic agents with activity against these resistant infectious diseases causing tricky invaders. IDSA is encouraged by the prospect of success for some agents currently in preclinical development to control infectious diseases caused by antibiotic resistance microbes. But still there is no evidence that this need will be fulfilled in the predictable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterial continues to stagnate, thereby risking the future pipeline of antibacterial drugs.

Related Companies/Industries:

  1. Abbott Diagnostics
  2. Alere Acquisition Update
  3. Thermo Fisher Scientific Inc.
  4. Alere Reader
  5. Beckman Coulter, Inc. / Danaher
  6. Becton, Dickinson and Company (BD)
  7. BD Max Molecular
  8. ID/AST
  9. POC Veritor
  10. bioMrieux Inc.
  11. Astellas Pharma
  12. Bayer
  13. AstraZeneca
  14. Chimerix Pharmaceuticals
  15. GlaxoSmithKline
  16. Novartis
  17. AMGEN

Related Associations and Societies:

  1. International Union of Microbiological Societies
  2. European Society of Clinical Microbiology and Infectious Diseases
  3. Federation of Infection Societies
  4. Canadian Society of Microbiologists
  5. British Infection Association
  6. Federation of European Microbiological Societies
  7. Welsh Microbiology Association
  8. Clinical Virology Network
  9. American Society for Microbiology
  10. Society for General Microbiology
  11. Infectious Diseases Society of America
  12. International Society for Infectious Diseases
  13. Clinical Infectious Diseases Society
  14. National Institute of Allergy and Infectious Disease
  15. Pediatric Infectious Diseases Society
  16. Institute for global health and infectious diseases
  17. International Union Against Tuberculosis and Lung Disease, Paris, France
  18. Australasian Society for Infectious Diseases
  19. Society of Infectious Diseases Pharmacists
  20. European Society for Paediatric Infectious Diseases

Epidemiological Data:

The most people deaths are caused by disease and injury categories. The report finds that the vast majority of environment-related deaths are due to cardiovascular diseases, such as stroke and ischaemic heart disease:

  1. Stroke – 2.5 million deaths annually
  2. Ischaemic heart disease – 2.3 million deaths annually
  3. Unintentional injuries (such as road traffic deaths) – 1.7 million deaths annually
  4. Cancers – 1.7 million deaths annually
  5. Chronic respiratory diseases – 1.4 million deaths annually
  6. Diarrhoeal diseases – 846 000 deaths annually
  7. Respiratory infections – 567 000 deaths annually
  8. Neonatal conditions – 270 000 deaths annually
  9. Malaria – 259 000 deaths annually
  10. Intentional injuries (such as suicides) – 246 000 deaths annually

Universities Related to Infectious Diseases

  1. Freie Universität Berlin, Germany
  2. Heidelberg University, Germany
  3. Humboldt-University, Germany
  4. Prussian Academy of Sciences, Germany
  5. Swedish University of Agricultural Sciences, Germany
  6. University of Gottingen, Germany
  7. Lübeck University, Germany
  8. Witten/Herdecke University, Germany
  9. Magdeburg University, Germany
  10. Mϋnster University, Germany
  11. Würzburg University, Germany
  12. Tϋbingen University, Germany
  13. Freiburg University, Germany
  14. Goethe University Frankfurt, Germany
  15. Leipzig University, Germany
  16. Deggendorf Institute of Technology, Germany
  17. HTW Berlin University of Applied Sciences, Germany
  18. Humboldt University of Berlin, Germany
  19. Free University of Berlin, Germany

Funds Allotment towards Infectious Diseases Research:

  1. Burroughs Welcome Fund (CAMS) for Medical Students - Up to $700,000
  2. Doris Duke Clinical Research International Fellowship for Medical Students-Up to $28,000
  3. American Association of University Women-International Fellowships- Up to $30,000
  4. American Cancer Society- Up to $45,000 annually
  5. American College of Physicians International Fellowship Exchange Program- Up to $7,000
  6. Christine Mirzayan Science and Technology Policy Graduate Fellowship Program-$8,000
  7. Elizabeth Glaser Pediatric AIDS Foundation Two-Year International Scholars Award-Up to $30,000

Companies in Berlin, Germany:

  1. Aenova
  2. Allied Clinical Management
  3. Alrise Biosystems
  4. Bavarian Nordic
  5. Bayer
  6. Berlin-Chemie (Menarini)
  7. Biogenes
  8. Biotronik
  9. Caprotec bioanalytics
  10. Celares
  11. Epigenomics
  12. Eternygen
  13. Ibt Bebig
  14. JPT Peptides Technologies (BioNTech)
  15. KCR
  16. Mologen
  17. Noxxon Pharma
  18. ProBioGen
  19. Provitro
  20. Roche
  21. Scienion
  22. Silence Therapeutics

Why Berlin, Germany:

Berlin is capital city of Germany with splendid textured history and, known as second most populous urban area in the European Union, located northern eastern Germany on the banks of Spree and Havel rivers and center of Berlin-Brandenburg Metropolitan Region by temperate seasonal climate. About one-third of city composed of incredible beauty in its forests, rivers, and historical sites, rivers, canals and lakes. It is almost as lively at night as it is during the day and it has a unique, exciting atmosphere, which provides the visitor with a truly unforgettable experience.

Berlin is Germany’s most important key features for health care for fastest growing economic sectors worldwide. The city is cluster of related companies and associations that includes 280 Medical Technology companies, 260 biotech and Pharmaceutical companies, with 130 clinics and 20+ large Research centers specializing in Health care and life sciences.

Most visited tourist Spots in Berlin, Germany:

  1. Pariser Platz
  2. Alexanderplatz
  3. Reichstag
  4. Brandenburg Gate
  5. Gendarmenmarkt
  6. Berlin Cathedral
  7. Museum Island
  8. Berlin Wall Memorial and Documentation Centre.
  9. Berlin Zoological Garden
  10. Pergamon Museum
  11. Hamburg
  12. Leipzig